Andrea Zivi is a Professor,University of Verona ,Italy

Andrea Zivi


Organizing Committee Member


University of Verona


1. Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L and Mancuso A, Darbepoetin alfa administered every three weeks (q3w) in anemic cancer patients receiving chemotherapy (CT), Anticancer Res. 2008 May-Jun;28(3B):1767-71

2. Bianchini D, Zivi A, Sandhu S and de Bono JS, Horizon scanning for novel therapeutics for the treatment of prostate cancer, Ann Oncol 2010 Oct;21 Suppl 7:vii43-vii55

3. Mancuso A, Sacchetta S, Saletti PC, Tronconi C, Milesi L, Garassino M, Martelli O, Leone A, Zivi A, Cerbone L, Recine F, Sollami R, Labianca R, Cavalli F, Sternberg CN, Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey, Anticancer Res, 2010 Oct;30(10):4289-95

4. Zivi A, Massard C, De-Bono J, Changing therapeutic paradigms in castrate-resistant prostate cancer, Clin Genitourin Cancer, 2010 Dec 1;8(1):17-22

5. Longo F, De Filippis L, Zivi A, Vitolo D, Del Signore E, Gori B, Diso D, Anile M, Venuta F, De Giacomo T, Coloni CF, Efficacy and tolerability of long-acting Octreotide in the treatment of thymic tumors: results of a pilot trial, Am J Clin Oncol, 2012 Apr;35(2):105-9

6. Attard G, Crespo M, Lim AC, Pope L, Zivi A, de Bono JS. Reporting the capture efficiency of a filterbased microdevice: a CTC is not a CTC unless it is CD45 negative -- Letter, Clin Cancer Res, 2011 May 1;17(9):3048-9

7. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM and Scher HI; COU-AA-301 Investigators, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med 2011 May 26,364(21):1995-2005.

8. Yap TA, Zivi A, Omlin A, de Bono JS The changing therapeutic landscape of castration-resistant prostate cancer, Nat Rev Clin Oncol 2011 Aug 9;8(10): 597-610.

9. de Bono JS, Bianchini D, Zivi A, Abiraterone and Increased Survival in Metastatic Prostate Cancer, Correspondence, N Engl J Med 2011 Aug 25, 365(8):766-768

10. Mancuso A, Di Paola ED, Leone A, Catalano A, Calabrò F, Cerbone L, Zivi A, Messina C, Alonso S, Vigna L, Caristo R, Sternberg CN, Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment, BJU Int. 2012 Jan; 109(2):200-6.

11. Zivi A, Cerbone L, Recine F, Sternberg CN, Safety and tolerability of pazopanib in the treatment of renal cell carcinoma, Expert Opin Drug Saf 2012 Sep;11(5):851-9

12. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators - Collaborators: Zivi A et al, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med 2012 Sep 27;367(13):1187-97 8

13. Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E, Hunt J, Sheridan E, Baikady B, Sarvadikar A, Maier G, Reid AHM, Mulick Cassidy A, Olmos D, Attard G, de Bono JS, Antitumor activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012; Nov;23(11):2943-7

14. Bianchini D, Omlin A, Pezaro C, Lorente D, Ferraldeschi R, Mukherji D, Crespo M, Figueiredo I, Miranda S, Riisnaes R, Zivi A, Buchbinder A, Rathkopf DE, Attard G, Scher HI, de Bono J, Danila DC, First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer, Br J Cancer 2013 Nov 12;109(10):2579-86

15. Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS, Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone, Eur J Cancer 2014 Jan;50(1):78-84

16. Lorente D, Bianchini D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, De Bono JS, Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer, Eur J Cancer. 2014 Mar;50(5):1042-3

17. Blagden S, Omlin A, Josephs DH, Stavraka C, Zivi A, Pinato DJ, Anthoney DA, Decordova S, Swales K, Riisnaes R, Pope L, Noguchi K, Shiokawa R, Inatani M, Prince J, Jones K, Twelves CJ, Spicer JF, Banerji U, First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics and pharmacodynamics, in patients with metastatic cancer, Clin Cancer Res 2014 Dec 1;20(23):5908-17. Erratum in: Clin Cancer Res. 2015 Feb 1;21(3):660. Olmin, Aurelius [corrected to Omlin, Aurelius].

18. Omlin A, Jones RJ, van der Noll R, Satoh T, Niwakawa M, Smith SA, Graham J, Ong M, Finkelman RD, Schellens JH, Zivi A, Crespo M, Riisnaes R, Nava-Rodrigues D, Malone MD, Dive C, Sloane R, Moore D, Alumkal JJ, Dymond A, Dickinson PA, Ranson M, Clack G, de Bono J, Elliott T, AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies, Invest New Drugs, 2015 Jun;33(3):679-90.

19. Khan KH, Yap TA, Ring A, Molife LR, Bodla S, Thomas K, Zivi A, Smith A, Judson I, Banerji U, de Bono JS, Kaye SB, Phase I trial outcomes in older patients with advanced solid tumours, Br J Cancer. 2016 Feb 2;114(3):262-8

20. Perez-Lopez R, Lorente D, Blackledge MD, Collins DJ, Mateo J, Bianchini D, Omlin A, Zivi A, Leach MO, de Bono JS, Koh DM, Tunariu N, Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer, Radiology. 2016 Jul;280(1):151-60.

21. Metcalf GA, Shibakawa A, Patel H, Sita-Lumsden A, Zivi A, Rama N, Bevan CL, Ladame S, Amplification-Free Detection of Circulating microRNA Biomarkers from Body Fluids Based on Fluorogenic Oligonucleotide-Templated Reaction between Engineered Peptide Nucleic Acid Probes: Application to Prostate Cancer Diagnosis, Anal Chem, 2016 Aug 16;88(16):8091-8


  • 2004 M.D. Catholic University of Sacred Heart, Rome, Italy (Summa Cum Laude)
  • 2005 M.D. Italian National Board Examination in General Medicine and Surgery
  • 2008 Medical Oncologist, “La Sapienza” University, Rome, Italy (Summa cum Laude)

Upcoming Conferences